CHMP Recommends EU Approval of VIZAMYL (Flutemetamol F18 Injection) for PET Imaging of Beta Amyloid Plaque

Targeted News Service |

FAIRFIELD, Conn., June 30 -- General Electric issued the following news release: GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This opinion recommends the granting of a marketing authorisation for VIZAMYL (Flutemetamol F18 injection), a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. VIZAMYLTM is for diagnostic use only and should be used in conjunction with a clinical evaluation. "The CHMP positive recommendation further strengthens GE Healthcare's longstanding commitment to the early and accurate detection of AD pathology and to improving quality of life for patients and their caregivers," said Kieran Murphy, President and CEO, Life Sciences, GE Healthcare. "When approved in the European Union, VIZAMYL will be an important tool to support assessments of patients with cognitive disorders, including AD." PET imaging with VIZAMYL detects the accumulation of beta amyloid in the brain, one of the pathological in-vivo markers of AD, and allows for visual interpretation of colour images. While VIZAMYL does not establish a diagnosis for AD or other cognitive disorders, it is a useful tool in conjunction with a clinical evaluation, and may have the potential to lead to earlier diagnosis and intervention in the future. "AD is a major unmet medical need and the lack of diagnostic tools increases the potential for diagnostic uncertainty and the risk of mismanagement," said Professor Philip Scheltens, Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center, Amsterdam. "Once approved, VIZAMYL may help physicians to assess specific patients with suspected Alzheimer's disease. This may help physicians determine appropriate treatment options, support patients and caregivers in planning for the future, and support clinical researchers in identifying patients for clinical trials." The CHMP positive opinion of VIZAMYL was based on review of pivotal and supportive data from a series of clinical trials, including several Phase III brain autopsy and biopsy studies which showed high sensitivity and specificity for visual interpretation of [18F]flutemetamol PET images, using beta amyloid pathology as the standard of truth.[i],[ii] In October 2013, the U.S. Food and Drug Administration (FDA) approved VIZAMYL for PET imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD or other causes of cognitive decline. GE Healthcare has developed and validated an electronic reader training program (ETP) to instruct U.S.-based physicians in accurate interpretation of VIZAMYL images. Images should be interpreted only by readers who have completed the GE Healthcare electronic reader training program that will be made available free of charge to healthcare professionals who want to conduct and interpret VIZAMYL imaging. Upon VIZAMYL approval, online and in-person training will be available in the European Union. GE'S COMMITMENT TO IMAGING RESEARCH [18F]Flutemetamol is one component of a broad portfolio of investigational diagnostic solutions that GE Healthcare is currently developing in the neurology field. GE Healthcare is taking a comprehensive approach to understanding dementia and AD through its ongoing research to uncover the causes, risks, and physical effects of the disease. GE Healthcare offers a broad portfolio of imaging resources including cyclotrons and chemistry systems to manufacture PET imaging agents, PET and MR scanners to scan patients, and is developing image analysis software to provide quantification, optimized visualization and reporting tools. Additionally, GE Healthcare is collaborating with the pharmaceutical industry to assist in their development of the next generation of therapies. To that end, we are working with potential partners in the industry to understand their strategic needs, and helping to provide imaging support for clinical trials of therapeutic agents. ---------- [i] Ikonomovic M, Buckley C, Smith A et al. [18F]Flutemetamol injection PET images reflect brain amyloid levels. Data presented at Alzheimer's Association International Conference 2012 (AAIC 2012), Vancouver, BC, Canada. [ii] Wolk D, Gamez J, Sadowsky C et. al. Brain autopsy and in vivo cortical brain biopsy trials show a strong concordance between [18F]Flutemetamol PET and amyloid-I pathology. Poster presented at: 64th Annual Meeting of the American Academy of Neurology, April 21-28, 2012; New Orleans, LA. TNS 30FurigayJof-140701-4784417 30FurigayJof

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
VBHLF Virgin Austrailia Hldg 0.17 0.00 0.00 0


Emerging Growth

Star Navigation Systems Group Ltd.

Star Navigation Systems Group Ltd is engaged in the development, marketing and promotion of in-flight safety monitoring systems.

Private Markets


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.